Syngene is a full-spectrum CRDMO that partners with companies across various sectors—including pharmaceuticals, biotechnology, animal health, consumer goods, and agrochemicals—to support research, development, and manufacturing needs.
The organization’s clients span from global powerhouses to startups and institutions in academia, government, and the non-profit space.
Since its inception in 1993, Syngene has operated with a differentiated model and is publicly listed on both the National and Bombay Stock Exchanges. Backed by a team of over 5,600 scientists and strong governance, it consistently delivers cutting-edge solutions for global healthcare challenges.
Frequently embedded within clients’ scientific teams, Syngene provides strategic, flexible, and scalable solutions that accelerate development cycles and enable faster product availability for patients.
Its innovative, integrated services cover the complete drug development continuum. Using the SynVent platform, Syngene streamlines advancement through various phases—from initial discovery and translational research to preclinical development—across both small molecules and biologics.
This approach offers clients a smoother, faster R&D journey while enabling Syngene to fully deploy its scientific and technical resources to maximum effect.
